InvestorsHub Logo
Post# of 47295
Next 10
Followers 41
Posts 5853
Boards Moderated 2
Alias Born 08/24/2008

Re: lowtrade post# 31121

Thursday, 04/26/2012 11:02:21 AM

Thursday, April 26, 2012 11:02:21 AM

Post# of 47295
Biodel • BIOD-Nasdaq
Market Outperform • Price 58 cents on April 16
by JMP Securities
Progress with insulin candidates bodes well for advancing clinical development; we are upgrading from Market Perform to Market Outperform rating and introducing a $3 price target. We believe that, based on positive top-line Phase I results... Biodel has identified a commercially viable, ultrafast-acting insulin candidate for progression into Phase II/III development. Importantly, we believe that, based on previous Phase III data and new trial-design considerations, the likelihood of success for this program in later-stage development is above average. Additionally, we point to continuing efforts with the ultra-fast-acting insulin analog and glucagon programs that may provide further clinical catalysts over the coming 12 to 24 months. While we acknowledge that the stock could continue to have a limited investor audience, we believe that there is now an opportunity for longer-term, value-focused investors to begin to accumulate shares. Market cap: $23 million.

GOLD & SILVER PICKS ON I-HUB
YOU'RE WELCOME, CLICK HERE

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.